AngioSafe
CA - San JoseBiotechnology
Focus: AngioSafe develops interventional cardiology devices, specifically peripheral artery occlusion crossing systems, positioning itself as a specialized player in the cardiovascular device space.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Open Jobs
5+3 this month
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Should You Work at AngioSafe?
AI assessmentHigh-risk, early-stage device venture best suited for mission-driven professionals comfortable with pre-commercial uncertainty and limited scale.
Why Work Here
- Early-stage device company with focused specialty in high-need cardiovascular intervention market
- Only 2 active job openings suggest selective, intentional hiring rather than rapid scaling
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AngioSafe Peripheral CTO Crossing System
Peripheral Artery OcclusionClinical Trials (1)
NCT04663867AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
N/AHelp build intelligence for AngioSafe
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.